We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.99 -0.2798% AAPL 236.12 0.4766% NVDA 141.89 2.8188% GOOGL 163.9 0.2937% GOOG 165.62 0.3453% AMZN 188.49 -0.2646% META 572.8 -0.6366% AVGO 179.26 -0.3502% TSLA 217.715 -1.3525% TSM 201.3996 0.3086% LLY 907.515 -1.1389% V 287.48 -1.0804% JPM 223.49 -0.8342% UNH 572.61 0.5267% NVO 117.1969 -0.7563% WMT 81.0075 -0.372% LVMUY 132.13 -2.3429% XOM 120.405 0.3291% LVMHF 664.5 -1.9483% MA 515.685 -0.1269%

Biovie Inc

Healthcare US BIVI

4.69USD
2.34(99.57%)

Last update at 2024-10-21T18:47:00Z

Day Range

3.817.50
LowHigh

52 Week Range

0.436.45
LowHigh

Fundamentals

  • Previous Close 2.35
  • Market Cap27.53M
  • Volume130671949
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-38.13670M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.93

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -50.25581M -26.08447M -130.24920M -16.67677M -2.44429M
Minority interest - - - - 0.00000M
Net income -50.25581M -22.79705M -130.80866M -21.44920M -2.39289M
Selling general administrative 11.55M 9.77M 4.64M 1.31M 1.26M
Selling and marketing expenses - - - - -
Gross profit -0.26684M -0.23742M -0.22938M -0.22938M -0.22938M
Reconciled depreciation 0.23M 0.23M 0.23M 0.23M 0.23M
Ebit -44.51818M -27.25298M -138.05414M -2.69289M -2.49657M
Ebitda -44.28881M -26.97952M -137.80279M -2.46328M -2.26604M
Depreciation and amortization 0.23M 0.27M 0.25M 0.23M 0.23M
Non operating income net other - 3.33M - - 0.00000M
Operating income -45.08045M -27.25298M -138.05414M -2.69289M -2.49657M
Other operating expenses 45.08M 27.25M 138.05M 2.69M 2.50M
Interest expense 4.30M 2.16M 0.56M 4.77M 0.00027M
Tax provision - - - - -
Interest income 0.56M 0.04M 0.02M 0.00023M 0.00116M
Net interest income -3.73789M -2.11891M -0.53748M -4.77219M 0.00089M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 4.30M -3.28742M 0.56M 4.77M -0.05140M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 45.08M 27.25M 138.05M 2.69M 2.50M
Cost of revenue 0.27M 0.24M 0.23M 0.23M 0.23M
Total other income expense net -1.43748M 1.17M 7.80M -13.98388M 0.05M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -50.25581M -26.08447M -130.24920M -16.67677M -2.44429M
Net income applicable to common shares -50.25581M -26.08447M -183.84752M -33.77583M -2.49295M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 35.10M 20.11M 6.05M 2.08M 2.57M
Intangible assets 0.64M 0.87M 1.10M 1.33M 1.55M
Earning assets - - - - -
Other current assets 0.10M 0.14M 0.09M 0.38M 0.33M
Total liab 19.76M 16.44M 1.00M 23.58M 0.44M
Total stockholder equity 15.34M 3.67M 5.05M -21.49864M 2.13M
Deferred long term liab - - - - 0.00000M
Other current liab 5.34M 4.13M 1.00M 21.41M 0.00000M
Common stock 0.00364M 0.00250M 0.00223M 0.00052M 0.05M
Capital stock 0.00364M 0.00250M 0.00223M 0.00052M 0.05M
Retained earnings -301.22571M -250.96989M -224.88542M -41.03790M -7.26207M
Other liab - 0.05M - - 0.00000M
Good will 0.35M 0.35M 0.35M 0.35M 0.35M
Other assets - 0.00456M - - 0.00000M
Cash 19.46M 18.64M 4.51M 0.04M 0.34M
Cash and equivalents - - - - -
Total current liabilities 14.49M 4.17M 1.00M 23.52M 0.44M
Current deferred revenue - - - - -
Net debt -5.04113M -6.37673M -4.51164M 0.87M -0.33992M
Short term debt 9.15M 0.04M - 0.85M 0.00000M
Short long term debt 9.11M - - 0.85M 0.00000M
Short long term debt total 14.42M 12.26M - 0.91M -
Other stockholder equity 316.39M 254.64M 229.93M 19.54M 9.34M
Property plant equipment 0.08M 0.12M - - 0.00000M
Total current assets 34.04M 18.78M 4.61M 0.41M 0.67M
Long term investments - - - - 0.00000M
Net tangible assets 14.36M 2.46M 3.61M -23.16957M 0.23M
Short term investments 14.48M - - - 0.00000M
Net receivables - - - - -
Long term debt 5.23M 12.14M - 0.06M 0.00000M
Inventory - - - - 0.00000M
Accounts payable 3.48M 2.44M 1.00M 1.26M 0.44M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 0.18M - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - 0.00250M 0.00223M 0.00052M 0.05M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - -250.96989M - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other - 0.00456M - - 1.90M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 1.06M 1.33M 1.44M 1.67M 1.90M
Capital lease obligations 0.09M 0.13M - - 0.00000M
Long term debt total - 12.14M - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -14.30114M -14.30114M -14.30114M -14.30114M 0.00000M
Change to liabilities 1.03M 2.80M -0.26283M 0.82M -0.11778M
Total cashflows from investing activities -14.30114M -14.30114M -14.30114M -14.30114M 0.00000M
Net borrowings - 14.61M -1.38582M 1.33M -0.24430M
Total cash from financing activities 55.37M 33.12M 14.93M 1.33M 2.80M
Change to operating activities -1.30389M 1.30M 0.28M -0.04163M -0.33415M
Net income -50.25581M -26.08447M -130.24920M -16.67677M -2.44429M
Change in cash 0.82M 14.13M 4.47M -0.30273M 0.29M
Begin period cash flow 18.64M 4.51M 0.04M 0.34M 0.05M
End period cash flow 19.46M 18.64M 4.51M 0.04M 0.34M
Total cash from operating activities -40.25288M -18.99085M -10.45305M -1.62823M -2.50158M
Issuance of capital stock 55.37M 18.51M 15.63M 15.63M 3.04M
Depreciation 0.23M 0.23M 0.23M 0.23M 0.23M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - 53.60M 17.10M 0.05M
Change to inventory - - - - 0.00000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - 18.51M - - -1.10148M
Other cashflows from financing activities 0.00224M 29.22M 1.12M 18.42M 2.99M
Change to netincome 9.87M 2.52M 119.55M 14.05M 0.17M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - 0.00000M
Cash flows other operating - 1.44M - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - 14.13M - - 0.00000M
Change in working capital -0.27044M 2.75M 0.02M 0.77M -0.45193M
Stock based compensation 6.38M 6.19M 3.02M 0.02M 0.06M
Other non cash items 1037.12M -2.08062M 124.87M 4.81M 0.05M
Free cash flow -40.25288M -18.99085M -10.45305M -1.62823M -2.50158M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BIVI
Biovie Inc		 2.34 99.57% 4.69 - - - 1.46 -11.6556
NVO
Novo Nordisk A/S		 -0.8931 0.76% 117.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 117.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.23 0.67% 482.30 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -17.68 1.78% 973.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Biovie Inc

680 West Nye Lane, Carson City, NV, United States, 89703

Key Executives

Name Title Year Born
Mr. Cuong Viet Do M.B.A., MBA Pres, CEO & Director 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corp. Sec. 1955
Dr. Joseph M. Palumbo M.D. Chief Medical Officer 1960
Dr. Penelope Markham Ph.D. Exec. VP of Liver Disease R&D 1966
Ms. Denise Smith Sr. VP of Manufacturing & Devel. NA
Dr. Christopher L. Reading Ph.D. Exec. VP of Neuroscience R&D 1948
Mr. Clarence N. Ahlem Exec. VP of Neuroscience Product Devel. 1955
Ms. Sarah Overton Hoit Chief Social Impact Officer 1967
Mr. Cuong Viet Do M.B.A. President, CEO & Director 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corporate Secretary 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.